Beijing Luzhu Biotechnology Co Ltd
HKEX:2480
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Borregaard ASA
OSE:BRG
|
NO |
|
Schroder BSC Social Impact Trust PLC
LSE:SBSI
|
UK |
|
Oilex Ltd
ASX:OEX
|
AU |
|
Premium Brands Holdings Corp
TSX:PBH
|
CA |
|
Geo Holdings Corp
TSE:2681
|
JP |
|
Cadence Design Systems Inc
NASDAQ:CDNS
|
US |
|
N
|
NNIT A/S
F:5NN
|
DK |
|
C
|
Cbrain A/S
XBER:C6F
|
DK |
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
B
|
Beijing Luzhu Biotechnology Co Ltd
HKEX:2480
|
4.5B HKD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
375.5B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
191.7B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
176.3B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.5B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.2B USD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
67.6B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
Beijing Luzhu Biotechnology Co Ltd
Glance View
Beijing Luzhu Biotechnology Co., Ltd. engages in the development, production, and sale of active pharmaceutical ingredients. The company is headquartered in Beijing, Beijing. The company went IPO on 2023-05-08. The firm is also engaged in out-licensing human vaccines and therapeutic biologics. Its products under clinical development include recombinant herpes zoster vaccine LZ901, and antibody injection products K3 and K193. Its LZ901 is mainly used to prevent herpes zoster caused by varicella zoster virus in adults aged 50 and above. The firm operates in the domestic market and overseas markets.
